Method and apparatus for merging vertical documents with horizontal
documents
    4.
    发明授权
    Method and apparatus for merging vertical documents with horizontal documents 失效
    将垂直文件与横向文件合并的方法和装置

    公开(公告)号:US5421699A

    公开(公告)日:1995-06-06

    申请号:US276683

    申请日:1994-07-18

    IPC分类号: B65H39/02 B65H39/06

    摘要: Apparatus and a method for merging vertically oriented documents with horizontally oriented documents. The apparatus includes: a document assembler for receiving vertically oriented documents, the document assembler having a pair of parallel paper paths, wherein each of the paper paths includes a device for transporting the vertically oriented documents and a device for stopping and a device for aligning the vertically oriented documents; a device located beneath the document assembler for re-orienting the documents from the document assembler in a vertical orientation to a horizontal orientation; and a horizontal transport located beneath the re-orienting device for feeding horizontally oriented documents toward the re-oriented documents emerging from the re-orienting device, whereby the horizontally oriented documents are merged with the re-oriented documents from the document assembler.

    摘要翻译: 用于将垂直定向文档与水平定向的文档合并的装置和方法。 该装置包括:用于接收垂直取向的文件的文档汇编器,该文档汇编器具有一对平行纸路径,其中每个纸路径包括用于传送垂直取向的文件的装置和用于停止的装置,以及用于对准 垂直文件; 位于文档汇编器下方的装置,用于将文档从文档汇编器以垂直取向重新定向到水平方向; 以及位于重新定向装置下面的水平传送器,用于将水平定向的文件朝向从重新定向装置出现的重新定向的文件供给,由此水平定向的文档与来自文档组装器的重新定向的文档合并。

    Diphenyl imidazoles as potassium channel modulators
    7.
    发明授权
    Diphenyl imidazoles as potassium channel modulators 有权
    二苯基咪唑作为钾通道调节剂

    公开(公告)号:US06271249B1

    公开(公告)日:2001-08-07

    申请号:US09538520

    申请日:2000-03-29

    IPC分类号: A61K31402

    摘要: Novel compounds of Formula 1 are useful to treat disorders responsive to openers of the large conductance calcium-activated potassium channels: wherein “Het” is one of a select group of heterocyclic moieties; Z is independently for each occurrence selected from O or S; Ra, Rb and Rc each are independently selected from hydrogen, halogen, OH, CF3, NO2, or provided Rc is not hydrogen; and when Ra and Rb are hydrogen, Rc may be a heterocyclic moiety selected from the group consisting of imidazol-1-yl, morpholinomethyl, N-methylimidazol-2-yl, and pyridin-2-yl; Rd and Re each are independently selected from hydrogen, halogen, CF3, NO2 or imidazol-1-yl; m, n and p each are independently selected from an integer of 0 or 1; and Rf and Rg each are independently hydrogen; C1-4 alkyl; or Rf and Rg, taken together with the nitrogen atom to which they are attached, is a heterocyclic moiety selected from the group consisting of N-methylpiperazine, morpholine, thiomorpholine, N-benzylpiperazine and imidazolinone.

    摘要翻译: 式1的新型化合物可用于治疗对大电导钙激活钾通道的开放剂起反应的病症:其中“Het”是选择性杂环部分组之一; Z独立地选自O或S; R a,R b和R c各自独立地选自氢,卤素,OH,CF 3,NO 2,或提供的R c不是氢; 当R a和R b为氢时,R c可以是选自咪唑-1-基,吗啉代甲基,N-甲基咪唑-2-基和吡啶-2-基的杂环部分; Rd和Re各自独立地选自氢,卤素,CF 3,NO 2或咪唑-1-基; m,n和p各自独立地选自0或1的整数; Rf和Rg各自独立地为氢; C 1-4烷基 或R f和R g与它们所连接的氮原子一起是选自N-甲基哌嗪,吗啉,硫代吗啉,N-苄基哌嗪和咪唑啉酮的杂环部分。